Castor launches RWE modular platform to harness RWD for post-marketing clinical trials

eClinical solution leader Castor launches modular RWE platform to harness RWD for post-marketing clinical trials. Castor RWE aims to reduce trial costs by 30% and deployment timelines to 4-weeks average by automating trial processes, integrating RWD and extending global reach.

On 10 November 2022, leading eClinical trial solution provider Castor announced the launch of Castor Real-World Evidence, a new modular platform created to harness RWD for post-marketing clinical trials (PMCT). By extending global reach, integrating RWD, and automating trial processes, Castor RWE aims to reduce trial costs by 30% and deployment timelines to 4-weeks on average.

“Real-world evidence has the potential to transform evidence-based medicine, by generating a body of evidence that provides a much more accurate view on what cure is best for each individual patient, through including a more diverse range of patients and in everyday settings,” proclaimed Castor CEO and co-founder Derk Arts. “Our latest offering simplifies the creation of RWE into clinical trials and supports life science companies in their pursuit of drug discovery and development goals.”

Castor is an established leading provider of decentralized and hybrid clinical trial solutions. Their new offering Castor RWE is a comprehensive platform of pre-configured modules and integrated technology designed to harness RWD for streamlined PMCT.

The platform addresses common PMCT challenges by readily integrating RWD sources such as patient-reported outcomes and wearables to increase patient access and retention as well as data quality and compliance, bringing human-centered design to the clinical trial process.

Castor RWE includes pre-configured modules for patient recruitment, eligibility screening, enrollment, data capture, and participant engagement. These features in one centralized platform, from recruitment to analysis, enable rapid deployment at scale, accelerate RWD capture, and expand access to global trial populations.

Castor believes its latest offering can reduce trial costs by 30% and deployment timelines to only 4-weeks on average. It will help sponsors uncover valuable insights into drug performance in global real-world settings, and improve the quality, security and reusability of RWD for researchers worldwide.

“We are committed to supporting life science companies in all aspects of their clinical trials, from early drug discovery to post-marketing studies,” asserted Castor CPTO Andy Sadler. “Castor RWE is a natural extension of our platform, and we are excited to provide this solution to our clients.”